Cytokinetics (CYTK) – Investment Analysts’ Weekly Ratings Changes

Cytokinetics (NASDAQ: CYTK) recently received a number of ratings updates from brokerages and research firms:

• 2/13/2025 – Cytokinetics was upgraded by analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating. They now have a $67.00 price target on the stock, down previously from $70.00.
• 2/7/2025 – Cytokinetics was upgraded by analysts at Evercore ISI to a “strong-buy” rating.
• 2/7/2025 – Cytokinetics had its “market outperform” rating reaffirmed by analysts at JMP Securities. They now have a $78.00 price target on the stock.
• 2/7/2025 – Cytokinetics is now covered by analysts at Citigroup Inc.. They set a “buy” rating and a $86.00 price target on the stock.
• 2/6/2025 – Cytokinetics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $72.00 price target on the stock.
• 1/22/2025 – Cytokinetics is now covered by analysts at Stifel Nicolaus. They set a “buy” rating and a $80.00 price target on the stock.
• 1/21/2025 – Cytokinetics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.
• 1/14/2025 – Cytokinetics had its “market outperform” rating reaffirmed by analysts at JMP Securities. They now have a $78.00 price target on the stock.
• 1/10/2025 – Cytokinetics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.
• 12/20/2024 – Cytokinetics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.
• 12/18/2024 – Cytokinetics had its price target raised by analysts at Royal Bank of Canada from $80.00 to $82.00. They now have an “outperform” rating on the stock.

Cytokinetics Stock Performance

CYTK opened at $41.62 on Friday. The company has a debt-to-equity ratio of 5.93, a current ratio of 9.28 and a quick ratio of 9.28. The business has a fifty day simple moving average of $47.61 and a 200 day simple moving average of $51.96. Cytokinetics, Incorporated has a 1 year low of $40.53 and a 1 year high of $81.36. The company has a market capitalization of $4.91 billion, a PE ratio of -7.74 and a beta of 0.83.

Insider Transactions at Cytokinetics

In other news, CEO Robert I. Blum sold 5,000 shares of Cytokinetics stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $50.76, for a total value of $253,800.00. Following the completion of the sale, the chief executive officer now directly owns 397,678 shares in the company, valued at approximately $20,186,135.28. The trade was a 1.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Fady Ibraham Malik sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $48.06, for a total value of $96,120.00. Following the completion of the sale, the executive vice president now owns 116,071 shares of the company’s stock, valued at approximately $5,578,372.26. This trade represents a 1.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 33,122 shares of company stock valued at $1,654,806. 3.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Cytokinetics

Institutional investors have recently modified their holdings of the stock. Capital International Investors bought a new position in shares of Cytokinetics in the fourth quarter worth $51,564,000. Norges Bank acquired a new stake in Cytokinetics during the fourth quarter worth about $46,556,000. Charles Schwab Investment Management Inc. increased its holdings in Cytokinetics by 42.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,321,391 shares of the biopharmaceutical company’s stock valued at $69,769,000 after buying an additional 395,709 shares during the period. Groupama Asset Managment acquired a new position in shares of Cytokinetics in the 4th quarter valued at approximately $16,464,000. Finally, Westfield Capital Management Co. LP lifted its holdings in shares of Cytokinetics by 38.9% during the 3rd quarter. Westfield Capital Management Co. LP now owns 1,212,886 shares of the biopharmaceutical company’s stock worth $64,040,000 after acquiring an additional 339,373 shares during the period.

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.